Sweden’s relatively low medicine prices are becoming part of the domestic debate over US Most Favoured Nation (MFN) pricing, with industry arguing that international price-linking could make the country less attractive for early launches and research investment.
The Swedish Association of the Pharmaceutical Industry (Läkemedelsindustriföreningen, Lif) published the warning on 8 July alongside a PwC analysis of Sweden’s pharmaceutical competitiveness. Lif reports that Sweden has the third-lowest list prices for originator medicines without generic competition among the European countries compared. It also cites list prices for new medicines at around 18% below the comparison-country average.
The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has reported the same 18% differential for new medicines, although it cautions that confidential rebates elsewhere limit comparisons of actual net prices.
MFN changes the strategic context for those public prices. US policy seeks to link American prices to lower prices in comparator markets. Lif argues that this increases the potential international consequence of accepting a relatively low Swedish price, potentially affecting decisions on launch timing, clinical research and investment.
Swedish authorities had already recognised the issue. In April, TLV postponed a proposed model of systematic recurring price reductions for medicines with high sales value, partly because MFN uncertainty could amplify risks to medicine availability. In June, the government expanded TLV’s international-pricing assignment to examine whether Sweden should alter its willingness to pay and what that would mean for access and pharmaceutical expenditure.
The July Lif analysis adds industry evidence to an emerging Swedish policy question: whether a pricing system designed primarily around domestic cost-effectiveness can retain relatively low public prices when those prices may increasingly influence returns in much larger markets.
Source: Swedish Association of the Pharmaceutical Industry
Link: Läkemedelsindustrin är en tillväxtmotor (The pharmaceutical industry is an engine for growth)
Date: 8 July 2026
Source: Dental and Pharmaceutical Benefits Agency
Link: Justerad metod och tidplan i riktlinje för subvention och prissättning av läkemedel (Adjusted method and timetable in guidelines for reimbursement and pricing of medicines)
Date: 27 April 2026
Source: Ministry of Health and Social Affairs
Link: Regeringen ändrar TLV uppdrag – ska även analysera betalningsvilja för läkemedel (Government changes TLV’s assignment – it must also analyse willingness to pay for medicines)
Date: 18 June 2026
